Autres langues Catalent, Inc. Berne S.E.

Actions

0C8

US1488061029

Temps Différé Berne S.E.			Varia. 5j.	Varia. 1 janv.
- ^CHF	-.--%		-.--%	-

03/08	Taysha Gene Therapies, Inc. et Catalent, Inc. étendent leur partenariat stratégique à la production commerciale de la thérapie génique TSHA-102 contre le syndrome de Rett	CI
03/08	Codis acquiert le site de Catalent à Nottingham, au Royaume-Uni, auprès de Catalent, Inc.	CI

Autres langues

25/08	Catalent, Inc. Completes Successful Debt Refinancing to Support Continued Growth and Innovation
03/08	Taysha Gene Therapies, Inc. and Catalent, Inc. Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
03/08	Codis acquired Catalent's facility in Nottingham, UK. from Catalent, Inc.
07/07	Nanoscope Therapeutics Expands Partnership With Catalent to Support Late-Phase Development and Commercial Supply of MCO-010
06/07	Codis agreed to acquire Catalent's facility in Nottingham, UK. from Catalent, Inc.
16/06	Catalent Launches Qai Enterprise AI Tool for Quality Management System Processes
13/05	Elpida Therapeutics and Catalent Enter Strategic Partnership for Late-Phase Aav Manufacturing
09/04	Cartherics Pty Ltd and Catalent Inc Expand Commercial License Agreement
11/03	Gelmedix and Catalent Enter Global Partnership for Development and Clinical Manufacturing of Ipsc-Derived Cell Therapies in Ocular and Retinal Diseases
18/02	Catalent and S.Biomedics Announces Partnership to Develop and Manufacture Ted-A9
12/01	Smartcella Holding AB and Catalent, Inc. Sign Nonexclusive License Agreement for Gmp Ipscs
04/11	Catalent, Inc.'s SMARTag ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego
04/09/25	Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
26/06/25	GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
23/04/25	Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
15/04/25	Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc
20/02/25	Catalent, Inc. Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to Its Board of Directors
19/02/25	Experts explore the future of iPSC-based cell therapies
04/02/25	Ardena Holding NV completed the acquisition of Oral Solids Development and Small-Scale Manufacturing Facility in Somerset, NJ from Catalent, Inc..
04/02/25	Ardena Holding NV acquired Drug product manufacturing facility in Somerset, New Jersey of Catalent, Inc.
04/02/25	Ardena Holding NV acquired Drug product manufacturing facility in Somerset, New Jersey of Catalent, Inc.
23/12/24	Catalent, Inc.(NYSE:CTLT) dropped from S&P 500 Value
23/12/24	Catalent, Inc.(NYSE:CTLT) dropped from S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index
23/12/24	Catalent, Inc.(NYSE:CTLT) dropped from S&P 500 Equal Weighted
23/12/24	Catalent, Inc.(NYSE:CTLT) dropped from S&P 500 - Pharmaceuticals